Exact Sciences (EXAS) Stock Forecast & Price Target

Compare

3,499 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EXAS Analyst Ratings

Strong Buy

17 Buy

2 Hold

0 Sell

Based on 19 analysts giving stock ratings to

Exact

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EXAS Stock 12 Month Forecast

Average Price Target

$75.47

▲(8.39% Upside)

Based on 19 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $75.47 with a high forecast of $100.00 and a low forecast of $46.91. The average price target represents a 8.39% change from the last price of $69.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"42":"$42","101":"$101","56.75":"$56.8","71.5":"$71.5","86.25":"$86.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$75.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$46.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[42,56.75,71.5,86.25,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.69,67.40615384615384,70.12230769230769,72.83846153846153,75.55461538461539,78.27076923076923,80.98692307692308,83.70307692307692,86.41923076923077,89.13538461538462,91.85153846153847,94.56769230769231,97.28384615384616,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.69,65.51923076923077,66.34846153846154,67.17769230769231,68.00692307692307,68.83615384615385,69.66538461538461,70.49461538461539,71.32384615384615,72.15307692307692,72.98230769230769,73.81153846153846,74.64076923076922,{"y":75.47,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,64.69,63.32230769230769,61.95461538461538,60.58692307692307,59.21923076923077,57.85153846153846,56.48384615384615,55.11615384615384,53.748461538461534,52.38076923076923,51.01307692307692,49.645384615384614,48.277692307692305,{"y":46.91,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":69.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.19,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.41,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.01,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.43,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.69,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$100.00

Average Price Target$75.47

Lowest Price Target$46.91

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Unknown Analyst

UBS

Not Ranked

UBS

$53→$80

Hold

14.89%

Upside

Reiterated

11/05/25

Exact Sciences (EXAS) Gets a Hold from UBS

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

11/04/25

Exact Sciences: Strong Growth Potential and Strategic Initiatives Justify Buy RatingWe believe there remains a long growth runway for Exact Sciences, even from “just” the core. The company has several irons in the fire with its pipeline—namely, MRD and multi-cancer—and those should support valuation expansion as more meaningful contributions come later this decade. For the here and now, what’s important is the Cologuard franchise has found its groove again and the last few quarters of execution should increase confidence in the team. We believe that shares continue to underappreciate the growth algorithm and that at a valuation of 4 times 2026 revenue, further execution on growth objectives (like we saw yesterday) should unlock additional value. We rate shares Outperform.

Catherine Ramsey Schulte

Robert W. Baird

$72→$88

Buy

26.38%

Upside

Reiterated

11/04/25

Exact Sciences price target raised to $88 from $72 at BairdExact Sciences price target raised to $88 from $72 at Baird

Tycho Peterson

Jefferies

$80→$90

Buy

29.25%

Upside

Reiterated

11/04/25

Jefferies Sticks to Its Buy Rating for Exact Sciences (EXAS)

Michael Ryskin

Bank of America Securities

$78

Buy

12.02%

Upside

Reiterated

11/04/25

Bank of America Securities Remains a Buy on Exact Sciences (EXAS)Raise our PO to $78, and reiterate Buy

Cira Diagnissa

TR | OpenAI - 4o

$68→$71

Hold

1.97%

Upside

Reiterated

11/04/25

AI Generated ArticleAI Generated Article

Vijay Kumar

Evercore ISI

$68→$80

Buy

14.89%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (NYSE: INSP) and Exact Sciences (NASDAQ: EXAS)

Daniel Arias

Stifel Nicolaus

$67→$80

Buy

14.89%

Upside

Reiterated

11/04/25

Exact Sciences price target raised to $80 from $67 at StifelExact Sciences price target raised to $80 from $67 at Stifel

Luke Sergott

Barclays

$65→$77

Buy

10.58%

Upside

Reiterated

11/04/25

Barclays Sticks to Its Buy Rating for Exact Sciences (EXAS)

Mark Massaro

BTIG

$75→$85

Buy

22.07%

Upside

Reiterated

11/04/25

Exact Sciences price target raised to $85 from $75 at BTIGExact Sciences price target raised to $85 from $75 at BTIG

Bruce Jackson

Benchmark Co.

$60→$75

Buy

7.71%

Upside

Reiterated

11/04/25

Exact Sciences (EXAS) Gets a Buy from Benchmark Co.

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

11/03/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Daniel Brennan

TD Cowen

$66→$90

Buy

29.25%

Upside

Reiterated

11/03/25

Exact Sciences: Strong Q3 Performance and Promising Outlook Drive Buy Rating and Increased Price Target

David Westenberg

Piper Sandler

$70

Buy

0.53%

Upside

Reiterated

10/28/25

Piper Sandler Sticks to Its Buy Rating for Exact Sciences (EXAS)

Kyle Mikson CFA

Canaccord Genuity

$75→$46.91

Buy

-32.63%

Downside

Reiterated

10/27/25

Exact Sciences (EXAS) Gets a Buy from Canaccord Genuity

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Unknown Analyst

UBS

Not Ranked

UBS

$53→$80

Hold

14.89%

Upside

Reiterated

11/05/25

Exact Sciences (EXAS) Gets a Hold from UBS

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

11/04/25

Catherine Ramsey Schulte

Robert W. Baird

$72→$88

Buy

26.38%

Upside

Reiterated

11/04/25

Exact Sciences price target raised to $88 from $72 at BairdExact Sciences price target raised to $88 from $72 at Baird

Tycho Peterson

Jefferies

$80→$90

Buy

29.25%

Upside

Reiterated

11/04/25

Jefferies Sticks to Its Buy Rating for Exact Sciences (EXAS)

Michael Ryskin

Bank of America Securities

$78

Buy

12.02%

Upside

Reiterated

11/04/25

Bank of America Securities Remains a Buy on Exact Sciences (EXAS)Raise our PO to $78, and reiterate Buy

Cira Diagnissa

TR | OpenAI - 4o

$68→$71

Hold

1.97%

Upside

Reiterated

11/04/25

AI Generated ArticleAI Generated Article

Vijay Kumar

Evercore ISI

$68→$80

Buy

14.89%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (NYSE: INSP) and Exact Sciences (NASDAQ: EXAS)

Daniel Arias

Stifel Nicolaus

$67→$80

Buy

14.89%

Upside

Reiterated

11/04/25

Exact Sciences price target raised to $80 from $67 at StifelExact Sciences price target raised to $80 from $67 at Stifel

Luke Sergott

Barclays

$65→$77

Buy

10.58%

Upside

Reiterated

11/04/25

Barclays Sticks to Its Buy Rating for Exact Sciences (EXAS)

Mark Massaro

BTIG

$75→$85

Buy

22.07%

Upside

Reiterated

11/04/25

Exact Sciences price target raised to $85 from $75 at BTIGExact Sciences price target raised to $85 from $75 at BTIG

Bruce Jackson

Benchmark Co.

$60→$75

Buy

7.71%

Upside

Reiterated

11/04/25

Exact Sciences (EXAS) Gets a Buy from Benchmark Co.

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

11/03/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Daniel Brennan

TD Cowen

$66→$90

Buy

29.25%

Upside

Reiterated

11/03/25

Exact Sciences: Strong Q3 Performance and Promising Outlook Drive Buy Rating and Increased Price Target

David Westenberg

Piper Sandler

$70

Buy

0.53%

Upside

Reiterated

10/28/25

Piper Sandler Sticks to Its Buy Rating for Exact Sciences (EXAS)

Kyle Mikson CFA

Canaccord Genuity

$75→$46.91

Buy

-32.63%

Downside

Reiterated

10/27/25

Exact Sciences (EXAS) Gets a Buy from Canaccord Genuity

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exact Sciences

1 Month

xxx

Success Rate

26/41 ratings generated profit

Average Return

+6.85%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.41% of your transactions generating a profit, with an average return of +6.85% per trade.

3 Months

xxx

Success Rate

22/32 ratings generated profit

Average Return

+6.62%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +6.62% per trade.

1 Year

William BonelloCraig-Hallum

Success Rate

16/19 ratings generated profit

Average Return

+62.15%

reiterated a buy rating 5 days ago

Copying William Bonello's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +62.15% per trade.

2 Years

xxx

Success Rate

18/19 ratings generated profit

Average Return

+127.47%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +127.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXAS Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EXAS has received 27 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. EXAS average Analyst price target in the past 3 months is 75.47.

Each month's total comprises the sum of three months' worth of ratings.

EXAS Financial Forecast

EXAS Earnings Forecast

Next quarter’s earnings estimate for EXAS is -$0.03 with a range of -$0.10 to $0.06. The previous quarter’s EPS was -$0.10. EXAS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year EXAS has Preformed in-line its overall industry.

EXAS Sales Forecast

Next quarter’s sales forecast for EXAS is $854.88M with a range of $824.54M to $865.00M. The previous quarter’s sales results were $850.74M. EXAS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year EXAS has Preformed in-line its overall industry.

EXAS Stock Forecast FAQ

What is EXAS’s average 12-month price target, according to analysts?

Based on analyst ratings, Exact Sciences Corp’s 12-month average price target is 75.47.

What is EXAS’s upside potential, based on the analysts’ average price target?

Exact Sciences Corp has 8.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EXAS a Buy, Sell or Hold?

Exact Sciences Corp has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.

What is Exact Sciences Corp’s price target?

The average price target for Exact Sciences Corp is 75.47. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $46.91. The average price target represents 8.39% Increase from the current price of $69.63.

What do analysts say about Exact Sciences Corp?

Exact Sciences Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of EXAS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Exact Sciences (EXAS) Stock Forecast & Price Target

EXAS Analyst Ratings

EXAS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exact Sciences

EXAS Analyst Recommendation Trends

EXAS Financial Forecast

EXAS Earnings Forecast

EXAS Sales Forecast

EXAS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts